IRIS
CASCINU, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.052
NA - Nord America 3.933
EU - Europa 2.979
SA - Sud America 2.180
AF - Africa 139
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 5
AN - Antartide 1
Totale 15.304
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.746
SG - Singapore 2.408
BR - Brasile 1.823
CN - Cina 1.578
HK - Hong Kong 954
SE - Svezia 782
VN - Vietnam 631
RO - Romania 549
IT - Italia 461
RU - Federazione Russa 364
DE - Germania 250
AR - Argentina 155
FI - Finlandia 113
GB - Regno Unito 110
IN - India 95
MX - Messico 76
CA - Canada 75
ID - Indonesia 68
BD - Bangladesh 66
AT - Austria 62
EC - Ecuador 61
ZA - Sudafrica 58
PL - Polonia 53
NL - Olanda 48
ES - Italia 45
JP - Giappone 42
CO - Colombia 37
TR - Turchia 36
FR - Francia 34
IQ - Iraq 34
IE - Irlanda 29
CL - Cile 24
PY - Paraguay 24
UA - Ucraina 23
VE - Venezuela 23
MA - Marocco 21
UZ - Uzbekistan 20
PK - Pakistan 18
EG - Egitto 17
IR - Iran 16
UY - Uruguay 16
LT - Lituania 15
PE - Perù 13
AE - Emirati Arabi Uniti 12
KE - Kenya 11
AZ - Azerbaigian 10
TN - Tunisia 10
AL - Albania 9
EU - Europa 9
IL - Israele 8
BY - Bielorussia 7
KZ - Kazakistan 7
OM - Oman 7
SA - Arabia Saudita 7
HN - Honduras 6
AO - Angola 5
AU - Australia 5
BE - Belgio 5
DZ - Algeria 5
JM - Giamaica 5
NP - Nepal 5
BO - Bolivia 4
LB - Libano 4
PA - Panama 4
XK - ???statistics.table.value.countryCode.XK??? 4
BB - Barbados 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
JO - Giordania 3
KW - Kuwait 3
MY - Malesia 3
NI - Nicaragua 3
PH - Filippine 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
A1 - Anonimo 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
MN - Mongolia 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RS - Serbia 2
SC - Seychelles 2
SN - Senegal 2
TH - Thailandia 2
TW - Taiwan 2
AQ - Antartide 1
BM - Bermuda 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
GT - Guatemala 1
HU - Ungheria 1
Totale 15.297
Salva come PNG Salva come JPEG
Città #
Dallas 1.256
Singapore 1.047
Hong Kong 952
Ashburn 390
Shanghai 383
Hefei 366
Lawrence 314
Princeton 313
Ho Chi Minh City 266
Beijing 246
New York 200
São Paulo 168
Moscow 141
Los Angeles 129
Hanoi 110
Helsinki 93
Milan 85
Boardman 71
Nuremberg 69
Munich 66
Rio de Janeiro 56
Warsaw 49
Rome 40
Tokyo 38
Belo Horizonte 36
Guangzhou 33
Haiphong 33
Stockholm 33
Brasília 32
Cesano Boscone 32
Denver 31
Poplar 31
Orem 30
Vienna 30
Brooklyn 29
Montreal 29
Dublin 28
Johannesburg 28
Chicago 27
Porto Alegre 27
Santa Clara 26
The Dalles 25
Chennai 24
London 24
Campinas 23
Curitiba 23
Guayaquil 22
Houston 22
Da Nang 21
Ribeirão Preto 21
Guarulhos 20
Ankara 19
Boston 19
Mexico City 19
Quito 19
Tashkent 19
Toronto 19
Columbus 18
Thái Bình 18
Amsterdam 17
Biên Hòa 17
Atlanta 16
Phoenix 16
Salvador 16
Buenos Aires 15
Montevideo 15
Dhaka 14
Hortolândia 14
Manchester 14
Recife 14
Turku 14
Blumenau 13
Frankfurt am Main 13
Mumbai 13
Querétaro 13
Tianjin 13
Contagem 12
Hải Dương 12
Manaus 12
Baghdad 11
Brescia 11
Duque de Caxias 11
Fortaleza 11
Nairobi 11
Niterói 11
Seattle 11
Sumaré 11
Volta Redonda 11
Washington 11
Xi'an 11
Cape Town 10
Carapicuíba 10
Ha Long 10
Jakarta 10
Lima 10
Pelotas 10
Romagnano Sesia 10
Shenzhen 10
Asunción 9
Baku 9
Totale 8.240
Salva come PNG Salva come JPEG
Nome #
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 389
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 381
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 373
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 315
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 112
DIET AND LIFESTYLE HABITS IN EARLY-ONSET COLORECTAL CANCER. A PILOT CASE-CONTROL STUDY 85
Advanced Digestive Neuroendocrine Tumors Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome 84
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 83
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 81
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 81
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe 80
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study 78
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 78
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 77
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 75
Early integration of palliative care in oncology practice: Results of the Italian Association of Medical Oncology (AIOM) survey 73
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 72
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes 71
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 71
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 70
Does immunotherapy change the treatment paradigm in metastatic gastric cancer? 68
Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic 68
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors 68
Metabolism and immune modulation in patients with solid tumors: Systematic review of preclinical and clinical evidence 67
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 66
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 66
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 66
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 66
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor 66
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 66
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives 65
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 64
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 64
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 64
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 63
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 63
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 63
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients 63
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 62
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 62
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 61
Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma 61
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 61
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 61
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 60
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 60
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 59
5-Fluorouracil pharmacogenomics: still rocking after all these years? 59
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 59
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 59
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW 58
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 58
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 57
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 57
Cholangiocarcinoma: new perspectives for new horizons 56
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 56
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial 55
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) 55
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 55
BRAF-mutated colorectal cancer: Clinical and molecular insights 54
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 54
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients 53
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 53
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life 52
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 52
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 51
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study 51
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer 51
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 51
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 51
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 50
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 50
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 49
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? 49
The Italian Rare Pancreatic Exocrine Cancer Initiative 49
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 49
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 48
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 47
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 47
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial 47
Evolution of surgical treatment of colorectal liver metastases in the real world: Single center experience in 1212 cases 47
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 47
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 47
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer 46
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 46
Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review 46
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 45
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 45
Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib 45
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 44
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 44
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 44
Dabrafenib-trametinib combination in 'field-practice': An Italian experience 44
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 44
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 44
Atezolizumab and bevacizumab in advanced HCC: ready for prime time? 44
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity 44
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 44
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 43
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 43
Totale 7.090
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 128.778
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021264 0 0 0 0 0 131 41 91 0 0 1 0
2021/2022229 0 1 0 99 7 7 23 43 19 7 6 17
2022/20231.524 736 283 86 8 13 201 41 73 59 6 10 8
2023/2024684 23 38 88 84 43 148 11 61 9 28 46 105
2024/20255.225 624 116 62 58 94 428 1.072 461 832 777 306 395
2025/20267.870 1.109 1.513 1.457 2.205 1.133 453 0 0 0 0 0 0
Totale 15.803